Blackstone’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
Blackstone's CYTK Position: Q2 2026 in Review
Blackstone increased its Cytokinetics (CYTK) stake by 7.6% in Q2 2026, buying an estimated $18.3K and bringing the position to 3,629 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #446.
Blackstone first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 486 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Blackstone held 3,629 shares of Cytokinetics worth $309K as of Q2 2026.
- Blackstone bought 255 Cytokinetics shares in Q2 2026, an estimated $18.3K.
- Cytokinetics made up ﹤0.01% of Blackstone's portfolio in Q2 2026, its #446 holding.
- Blackstone first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
- 486 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Blackstone's 13F filing for Q2 2026, filed 14 Aug 2026.